BMF 219
Alternative Names: BMF-219; Covalent menin inhibitor - Biomea FusionLatest Information Update: 03 Oct 2024
At a glance
- Originator Biomea Fusion
- Class Antihyperglycaemics; Antineoplastics; Morpholines; Piperidines; Pyridines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Menin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 26 Sep 2024 US FDA lifts the clinical hold on phase I/II COVALENT-112 in Type 1 diabetes mellitus
- 26 Sep 2024 US FDA lifts the clinical hold on phase I/II COVALENT-111 in Type 2 diabetes mellitus
- 06 Jun 2024 Biomea Fusion suspends a phase II COVALENT-112 trial for Type 1 diabetes mellitus in Canada and USA(PO) (NCT06152042)